Empire Genomics Licenses Affy's Microarray Patents for Dx Development | GenomeWeb
NEW YORK (GenomeWeb News) — Affymetrix has licensed several of its microarray-related patents to Empire Genomics, Affy said today.
 
Under the non-exclusive agreement, Empire Genomics, a Buffalo, NY-based molecular diagnostics company, will use Affy’s technology to manufacture, use, and sell DNA chips and related products and services for comparative genomic hybridization, Affy said.
  
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.